Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023;30(3):391-400.
doi: 10.5603/CJ.a2021.0084. Epub 2021 Aug 6.

Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis

Alexandra Bálint  1 , Lilla Hanák  2 , Péter Hegyi  2 , Zsolt Szakács  2   3 , Szimonetta Eitmann  2 , András Garami  4 , Margit Solymár  2 , Katalin Márta  2 , Zoltán Rumbus  4 , András Komócsi  5
Affiliations
Meta-Analysis

Increased risk of adverse events in patients with low-on clopidogrel platelet reactivity after percutaneous coronary intervention: A systematic review and meta-analysis

Alexandra Bálint et al. Cardiol J. 2023.

Abstract

Background: Clinical evidence has been controversial regarding the influence of low platelet reactivity (LPR), ischemic and bleeding outcomes among patients receiving coronary stent implantation. Hence, the present study performed a meta-analysis to systematically evaluate the significance of LPR on adverse cardiovascular events.

Methods: MEDLINE, EMBASE and CENTRAL databases were searched up to November 2020 for relevant studies including patients with acute coronary syndrome undergoing percutaneous coronary intervention. LPR was the exposed arm while the non-LPR group represented the control. The primary outcome of interest was bleeding risk including major and minor bleeding events. Secondary outcomes included all-cause mortality, repeated revascularization, nonfatal myocardial infarction, and stent thrombosis. Study-level outcomes were evaluated in random-effect models.

Results: A total of 20 studies with 19,064 patients were included. Pooled analysis showed that LPR was associated with an increased bleeding risk (relative risk [RR] 2.80, 95% confidence interval [CI] 1.95-4.02, p < 0.01). Patients with LPR had a lower risk of non-fatal myocardial infarction (RR 0.59, 95% CI 0.38-0.91, p < 0.05) and of serious vascular events (RR 0.50, 95% CI 0.30-0.84, p < 0.01).

Conclusions: Low platelet reactivity is associated with an increased bleeding risk of patients who underwent coronary stent implantation. The results suggest possible benefits of this marker in risk stratification, with potential improvement in risk prediction. There are potential advantages using combinations with other factors in prediction models, however, they require further study. PROSPERO registration number: CRD42019136393).

Keywords: acute coronary syndrome; bleeding risk; clopidogrel; low platelet reactivity; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Dr. András Komócsi reports personal fees from Bayer Pharma AG, Pfizer, Krka, d. d., Merck & Co., and Servier, outside of the submitted work. The other authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Figure 2
Figure 2
Principal pooled analysis. Forest plots of major and minor bleeding risk in studies following percutaneous coronary intervention with low platelet reactivity (LPR) versus without LPR. The grey rectangles are proportional with the study weight. The diamond represents the cumulative odds ratio (OR) and confidence interval (CI).
Figure 3
Figure 3
Summary of the outcomes of the secondary endpoints. The diamond represents the cumulative risk ratio and confidence interval (CI) of all patient groups. *Mean difference (95% CI); LPR — low platelet reactivity; MI — myocardial infarction.
See this image and copyright information in PMC

References

    1. Montalescot G, Sechtem U, Achenbach S, et al. ESC Committee for Practice Guidelines, Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003. doi: 10.1093/eurheartj/eht296. - DOI - PubMed
    1. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi: 10.1056/NEJMoa0706482. - DOI - PubMed
    1. Wallentin L, Becker RC, Budaj A, et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi: 10.1056/NEJMoa0904327. - DOI - PubMed
    1. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2317. doi: 10.1016/j.jacc.2007.01.094. - DOI - PubMed
    1. Cuisset T, Cayla G, Frere C, et al. Predictive value of posttreatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention. 2009;5(3):325–329. doi: 10.4244/51. - DOI - PubMed

MeSH terms

Substances